… ory of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding).
History of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy.
Severe heart failure (NYHA Class IV), renal failure or hepatic failure (see section 4.4).
Last trimester of pregnancy (see section 4.6).
Identical in all 3 labels. Surrounding text shown from McNeil Products Ltd.
… gs.
Active or previous peptic ulcer (two or more distinct episodes of proven ulceration or bleeding).
History of upper gastrointestinal bleeding or perforation, related to previous NSAIDs therapy.
Patients with severe hepatic failure, renal failure or severe heart failure (NYHA Class IV) (see section 4.4).
Use in last trimester of pregnancy (see section 4.6 Fertility, Pregnancy and Lactation).
… tory of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding).
History of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy.
Severe heart failure (NYHA Class IV), renal failure or hepatic failure (see section 4.4)
Last trimester of pregnancy
… astrointestinal haemorrhage (two or more distinct episodes of proven ulceration or bleeding).
Ibuprofen should not be given to patients with conditions involving an increased tendency to bleeding.
Ibuprofen is contraindicated in patients with severe heart failure (NYHA Class IV), hepatic failure and renal failure (see section 4.4).
Use during pregnancy
Ibuprofen is contraindicated during the third trimester of pregnancy (see section 4.6).
… trointestinal bleeding or perforation, related to previous NSAIDs therapy - active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding) - severe renal failure or severe hepatic failure (see section 4.4). - severe heart failure (NYHA Class IV) - last trimester of pregnancy (see section 4.6) - significant dehydration (caused by vomiting, diarrhoea or insufficient fluid intake) - cerebrovascular or othe …
… s, pain-relievers or decongestants.
• Patients receiving tricyclic antidepressants.
• Patients currently receiving, or who have within the last two weeks received, monoamine oxidase inhibitors.
• Patients with severe heart failure (NYHA Class IV), renal failure or hepatic failure (see section 4.4).
• During pregnancy and breast-feeding. (see section 4.6).